Today,
medical devices field seeks to provide improved health care by
focusing on the use of in vitro diagnostic tools. These tools assist
in screening, diagnosis, staging as well as disease management for
selection of drugs and dosage. D-dimer test is used as a screening
test to diagnose thrombosis and consequently rule out conditions of
deep vein thrombosis (DVT), pulmonary embolism (PE) and/or
disseminated intravascular coagulation (DIC). D-dimer tests avoid
unnecessary imaging procedures and treatment and reduce hospital
stays. The test avoids risks associated with invasive procedures. The
prominent drivers of D-dimer tests include non-invasiveness, device
compactness and elimination of radiological intervention.
Theglobal D-dimer testing market is segmented broadly into testing
methods, applications and geography. The testing methods are further
segmented into point-of-care tests and laboratory tests. Laboratory
testing is the most commonly used method in market since decades.
Laboratory tests are categorized into coagulation analyzers and
clinical chemistry analyzers. Point-of-care tests help in meeting the
demand of quick turnaround time, thus accelerate reliable results.
Hence, these tests are likely to have rapid growth in the near
future. The three major disease applications for D-dimer testing
include DVT, PE and DIC.
Major
growth drivers for the global D-dimer testing market include rise in
the number of patients demanding coagulation testing, various
technological advancements such as introduction of highly sensitive
and specific hemostasis markers for automated instruments, and
monitoring of patients on anti-coagulation therapy. However,
interpretation of D-dimer levels in the aged population remains a
major challenge. This has been attributed to the dramatic increase in
rate of thrombosis with age, thus rendering D-dimer test less useful
in excluding DVT or PE. Clinical acceptance of point-of-care D-dimer
tests by hospitals and clinics is another obstacle in the market
growth. Poor bioequivalence compared to laboratory services raises
concerns regarding the acceptability of POC device in emergency
departments. Since last few years, detection of PE based on clinical
symptoms has become complicated demanding the development of fully
automated coagulation analyzers capable of running tests based on
multiple methods with increased safety, precision, and accuracy
compared with manual methods.
Geographically,
North America accounts for the largest market share in terms of
revenue in 2013 and is expected to maintain its position by the end
of forecast period. North America is followed by Europe in term of
number of D-dimer tests performed across the globe. Increasing
research activities to improve specificity of D-dimer tests in order
to identify the presence of any coagulation diseases such as DVT, PE
and DIC are the major drivers of the D-dimer market in Europe.
According to the Society of Interventional Radiology (U.S.), about
600,000 new cases of DVT are diagnosed in the U.S. each year. An
increase in the number of laboratories and growing demand for D-dimer
POC tests, development of public health care systems, rising interest
of big pharmaceutical players, and increasing population, are several
factors expected to drive the D-dimer testing market in Asia-Pacific,
Latin America and MENA regions.
The
key players contributing to the global D-dimer testing market include
Abbott Laboratories, Alere, Inc., Beckman Coulter, Inc., Bio/Data
Corporation, Becton, Dickinson and Company, Corgenix, F. Hoffman-La
Roche Ltd., Helena Biosciences, Siemens Healthcare, Sysmex
Corporation, Thermo Fisher Scientific, and Trinity Biotech. The
future holds challenges for the market leaders and niche suppliers
due to continuous expansion through acquisitions and growing number
of customers.
Request for a Brochure to Know More -
Comments
Post a Comment